- Document Number:
20250108022
- Appl. No:
18/655854
- Application Filed:
May 06, 2024
- نبذة مختصرة :
The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RARγ agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.
- Claim:
1. (canceled)
- Claim:
2. A method comprising administering a therapeutically effective amount of a composition comprising 4-[(E)-2-[5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-3-(1H-pyrazol-1-ylmethyl)-2-naphthalenyl]-ethenyl]benzoic acid or a pharmaceutically acceptable salt thereof to an eye of a subject in need thereof.
- Claim:
3. The method of claim 2, wherein the subject has corneal dystrophy.
- Claim:
4. The method of claim 2, wherein the subject has retinal dystrophy.
- Claim:
5. The method of claim 2, wherein the subject has conal dystrophy.
- Claim:
6. The method of claim 2, wherein the composition is formulated for ocular administration.
- Claim:
7. The method of claim 2, wherein the composition is administered daily.
- Claim:
8. The method of claim 2, wherein the composition is administered twice daily.
- Claim:
9. The method of claim 2, wherein the composition is administered over a period of at least one week.
- Claim:
10. A composition comprising 4-[(E)-2-[5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-3-(1H-pyrazol-1-ylmethyl)-2-naphthalenyl]-ethenyl]benzoic acid or a pharmaceutically acceptable salt thereof, formulated for ocular administration.
- Claim:
11. The composition of claim 10, further comprising a pharmaceutically acceptable carrier.
- Claim:
12. The composition of claim 11, wherein the pharmaceutically acceptable carrier comprises a pH buffered solution.
- Claim:
13. The composition of claim 11, wherein the pharmaceutically acceptable carrier comprises a polyol.
- Claim:
14. The composition of claim 11, wherein the pharmaceutically acceptable carrier comprises an ester.
- Claim:
15. The composition of claim 11, wherein the pharmaceutically acceptable carrier comprises an oil.
- Current International Class:
61; 61; 61; 61; 61; 61
- الرقم المعرف:
edspap.20250108022
Processing Request
No Comments.